Achieve Life Sciences, Inc.
$7.98
$0.07 (+0.88%)
$7.80Day Range$8.09
Key Statistics
Market Cap
$813.96M
Shares Outstanding
102.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 12, 1995
Round Lot
100
Locale
US
Trading Data
Day Open
$7.91
Day High
$8.09
Day Low
$7.80
Volume
2.83M
VWAP
$7.98
Prev Close
$7.91
Transactions
--
Acc. Volume
--
About Achieve Life Sciences, Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESSIC 283528 employees22722 29TH DR. SE, SEATTLE, WA, 98021425-686-1500IPO Oct 12, 1995US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000949858
- Composite FIGI
- BBG000FB8S62
- Share Class FIGI
- BBG001S8JF14
- Ticker Root
- ACHV
- SIC Code
- 2835
About Achieve Life Sciences, Inc. (ACHV) Stock
Achieve Life Sciences, Inc. (ACHV) closed the 2026-09-18 session at $7.98, up 0.88% versus the previous close (+0.07). The stock opened at $7.91 and traded between $7.80 and $8.09 during that session. Session trading volume was 2.8M shares. The volume-weighted average price (VWAP) is $7.98.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
Achieve Life Sciences, Inc. has a market capitalization of $814.0 million. The company operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry classification. ACHV is listed on the XNAS exchange. The company employs approximately 28 people. Achieve Life Sciences, Inc. is headquartered in SEATTLE, WA. The recorded listing date is 1995-10-12.
On this page you can find market ACHV stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector.